A novel self-replicating chimeric lentivirus-like particle

Journal of Virology

Volumn 86, Issue 1, 2012, Pages 246-261

  Jurgens, Christy K ^a,b,c,f   Young, Kelly R ^a,b,c   Madden, Victoria J ^d   Johnson, Philip R ^e   Johnston, Robert E ^a,b,c  

^a Carolina Vaccine Institute   (United States)

^b Department of Microbiology and Immunology ^*  (United States)

^c Global Vaccines Inc   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; LIVE VACCINE; PROTEINASE; VIRUS ENVELOPE PROTEIN; VIRUS LIKE PARTICLE VACCINE; VIRUS RNA; VIRUS VACCINE;

ANIMAL CELL; ARTICLE; CD4+ T LYMPHOCYTE; CELL CULTURE; CONTROLLED STUDY; DRUG SAFETY; ENVELOPE GENE; FEASIBILITY STUDY; GENE EXPRESSION; GROUP SPECIFIC ANTIGEN GENE; HUMAN; HUMAN CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN EXPRESSION; RNA REPLICATION; SHIV89 6P GENE; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINE PRODUCTION; VENEZUELAN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS; VIRION; VIRUS ATTENUATION; VIRUS GENE; VIRUS GENOME; VIRUS LIKE AGENT;

AIDS VACCINES; ANIMALS; CELL LINE; CHIMERA; ENCEPHALITIS VIRUS, VENEZUELAN EQUINE; GENE EXPRESSION; GENE PRODUCTS, ENV; GENE PRODUCTS, GAG; GENETIC VECTORS; HIV INFECTIONS; HUMANS; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS ASSEMBLY; VIRUS REPLICATION;

ALPHAVIRUS; HUMAN IMMUNODEFICIENCY VIRUS; LENTIVIRUS; PRIMATES; SIMIAN IMMUNODEFICIENCY VIRUS; VENEZUELAN EQUINE ENCEPHALITIS VIRUS;

EID: 84855980515     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.05191-11     Document Type: Article

References (59)

1. Barnett SW, et al. 2010. Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant. J. Virol. 84:5975-5985.
2. Briggs JA, Krausslich HG. 2011. The molecular architecture of HIV. J. Mol. Biol. 410:491-500.
3. Caley IJ, et al. 1999. Venezuelan equine encephalitis virus vectors expressing HIV-1 proteins: vector design strategies for improved vaccine efficacy. Vaccine 17:3124-3135.
4. Caley IJ, et al. 1997. Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector. J. Virol. 71: 3031-3038.
5. Cecil C, et al. 2007. Structure and immunogenicity of alternative forms of the simian immunodeficiency virus gag protein expressed using Venezuelan equine encephalitis virus replicon particles. Virology 362:362-373.
6. Chen P, Hubner W, Riviere K, Liu YX, Chen BK. 2006. Chimeric HIV-1 containing SIV matrix exhibit enhanced assembly in murine cells and replicate in a cell-type-dependent manner in human T cells. Virology 349:1-12.
7. Chertova E, et al. 2002. Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus. J. Virol. 76:5315-5325.
8. Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC. 1992. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 258:1938 -1941.
9. Davis NL, Brown KW, Johnston RE. 1996. A viral vaccine vector that expresses foreign genes in lymph nodes and protects against mucosal challenge. J. Virol. 70:3781-3787.
10. Davis NL, et al. 2002. Alphavirus replicon particles as candidate HIV vaccines. IUBMB Life 53:209 -211.
11. Desrosiers RC. 2004. Prospects for an AIDS vaccine. Nat. Med. 10: 221-223.
12. Freed EO, Martin MA. 1996. Domains of the human immunodeficiency virus type 1 matrix and gp41 cytoplasmic tail required for envelope incorporation into virions. J. Virol. 70:341-351.
13. Frolova E, Frolov I, Schlesinger S. 1997. Packaging signals in alphaviruses. J. Virol. 71:248 -258.
14. Ganser-Pornillos BK, Yeager M, Sundquist WI. 2008. The structural biology of HIV assembly. Curr. Opin. Struct. Biol. 18:203-217.
15. Geigenmuller-Gnirke U, Nitschko H, Schlesinger S. 1993. Deletion analysis of the capsid protein of Sindbis virus: identification of the RNA binding region. J. Virol. 67:1620-1626.
16. Gonzalez SA, Burny A, Affranchino JL. 1996. Identification of domains in the simian immunodeficiency virus matrix protein essential for assembly and envelope glycoprotein incorporation. J. Virol. 70:6384-6389.
17. Grigorov B, et al. 2007. Intracellular HIV-1 Gag localization is impaired by mutations in the nucleocapsid zinc fingers. Retrovirology 4:54.
18. Hansen SG, et al. 2009. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat. Med. 15:293-299.
19. Higuchi R, Krummel B, Saiki RK. 1988. A general method of in vitro preparation and specific mutagenesis of DNA fragments: study of protein and DNA interactions. Nucleic Acids Res. 16:7351-7367.
20. Ido E, Han HP, Kezdy FJ, Tang J. 1991. Kinetic studies of human immunodeficiency virus type 1 protease and its active-site hydrogen bond mutant A28S. J. Biol. Chem. 266:24359 -24366.
21. Jacks T, et al. 1988. Characterization of ribosomal frameshifting in HIV-1 gag-pol expression. Nature 331:280 -283.
22. Johnson RP, et al. 1999. Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation. J. Virol. 73: 4952-4961.
23. Karacostas V, Wolffe EJ, Nagashima K, Gonda MA, Moss B. 1993. Overexpression of the HIV-1 gag-pol polyprotein results in intracellular activation of HIV-1 protease and inhibition of assembly and budding of virus-like particles. Virology 193:661- 671.
24. Kohl NE, et al. 1988. Active human immunodeficiency virus protease is required for viral infectivity. Proc. Natl. Acad. Sci. U. S. A. 85:4686-4690.
25. Lebedeva I, Fujita K, Nihrane A, Silver J. 1997. Infectious particles derived from Semliki Forest virus vectors encoding murine leukemia virus envelopes. J. Virol. 71:7061-7067.
26. Letvin NL. 2005. Progress toward an HIV vaccine. Annu. Rev. Med. 56: 213-223.
27. Luban J, Goff SP. 1994. Mutational analysis of cis-acting packaging signals in human immunodeficiency virus type 1 RNA. J. Virol. 68: 3784-3793.
28. Muriaux D, Mirro J, Harvin D, Rein A. 2001. RNA is a structural element in retrovirus particles. Proc. Natl. Acad. Sci. U. S. A. 98:5246 -5251.
29. Nature Publishing Group. 2007. HIV vaccine failure prompts Merck to halt trial. Nature 449:390.
30. Nordqvist A, Fenyo EM. 2005. Plaque-reduction assays for human and simian immunodeficiency virus neutralization. Methods Mol. Biol. 304: 273-285.
31. Norley S, Beer B, Binninger-Schinzel D, Cosma C, Kurth R. 1996. Protection from pathogenic SIVmac challenge following short-term infection with a nef-deficient attenuated virus. Virology 219:195-205.
32. Park J, Morrow CD. 1991. Overexpression of the gag-pol precursor from human immunodeficiency virus type 1 proviral genomes results in efficient proteolytic processing in the absence of virion production. J. Virol. 65:5111-5117.
33. Parolin C, Dorfman T, Palu G, Gottlinger H, Sodroski J. 1994. Analysis in human immunodeficiency virus type 1 vectors of cis-acting sequences that affect gene transfer into human lymphocytes. J. Virol. 68:3888 -3895.
34. Paul NL, et al. 1993. Expression of HIV-1 envelope glycoproteins by Semliki Forest virus vectors. AIDS Res. Hum. Retroviruses 9:963-970.
35. Perri S, et al. 2003. An alphavirus replicon particle chimera derived from Venezuelan equine encephalitis and Sindbis viruses is a potent gene-based vaccine delivery vector. J. Virol. 77:10394 -10403.
36. Pitisuttithum P, et al. 2006. Randomized, double-blind, placebocontrolled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis. 194:1661-1671.
37. Piver E, Collin C, Renault N, Bru T, Pages JC. 2006. Mobilization of full-length Semliki Forest virus replicon by retrovirus particles. J. Virol. 80:9889 -9895.
38. Pushko P, et al. 1997. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology 239: 389-401.
39. Quetglas JI, et al. 2010. Alphavirus vectors for cancer therapy. Virus Res. 153:179 -196.
40. Raju R, Huang HV. 1991. Analysis of Sindbis virus promoter recognition in vivo, using novel vectors with two subgenomic mRNA promoters. J. Virol. 65:2501-2510.
41. Reed L, Muench H. 1938. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27:493-497.
42. Rerks-Ngarm S, et al. 2009. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361:2209 -2220.
43. Rulli SJ, Jr, et al. 2007. Selective and nonselective packaging of cellular RNAs in retrovirus particles. J. Virol. 81:6623- 6631.
44. Schlesinger S, Dubensky TW. 1999. Alphavirus vectors for gene expression and vaccines. Curr. Opin. Biotechnol. 10:434-439.
45. Shi Y, Albert J, Francis G, Holmes H, Fenyo EM. 2002. A new cell line-based neutralization assay for primary HIV type 1 isolates. AIDS Res. Hum. Retroviruses 18:957-967.
46. Smith AJ, Srinivasakumar N, Hammarskjold ML, Rekosh D. 1993. Requirements for incorporation of Pr160[supi]gag-pol from human immunodeficiency virus type 1 into virus-like particles. J. Virol. 67: 2266-2275.
47. Spearman P. 2006. Current progress in the development of HIV vaccines. Curr. Pharm. Des. 12:1147-1167.
48. Tanchou V, et al. 1998. Role of the N-terminal zinc finger of human immunodeficiency virus type 1 nucleocapsid protein in virus structure and replication. J. Virol. 72:4442-4447.
49. Thompson JM, et al. 2006. Mucosal and systemic adjuvant activity of alphavirus replicon particles. Proc. Natl. Acad. Sci. U. S. A. 103: 3722-3727.
50. Tubulekas I, Berglund P, Fleeton M, Liljestrom P. 1997. Alphavirus expression vectors and their use as recombinant vaccines: a minireview. Gene 190:191-195.
51. Weiss B, Geigenmuller-Gnirke U, Schlesinger S. 1994. Interactions between Sindbis virus RNAs and a 68 amino acid derivative of the viral capsid protein further defines the capsid binding site. Nucleic Acids Res. 22:780 -786.
52. Weiss B, Nitschko H, Ghattas I, Wright R, Schlesinger S. 1989. Evidence for specificity in the encapsidation of Sindbis virus RNAs. J. Virol. 63: 5310-5318.
53. Welker R, Hohenberg H, Tessmer U, Huckhagel C, Krausslich HG. 2000. Biochemical and structural analysis of isolated mature cores of human immunodeficiency virus type 1. J. Virol. 74:1168 -1177.
54. White LJ, Wang JG, Davis NL, Johnston RE. 2001. Role of alpha/beta interferon in Venezuelan equine encephalitis virus pathogenesis: effect of an attenuating mutation in the 5= untranslated region. J. Virol. 75: 3706-3718.
55. Whitney JB, Ruprecht RM. 2004. Live attenuated HIV vaccines: pitfalls and prospects. Curr. Opin. Infect. Dis. 17:17-26.
56. Winstone N, et al. 2011. Enhanced control of pathogenic SIVmac239 replication in macaques immunized with a plasmid IL12 and a DNA prime, viral vector boost vaccine regimen. J. Virol. 85:9578-9587.
57. Yang X, Kurteva S, Ren X, Lee S, Sodroski J. 2005. Stoichiometry of envelope glycoprotein trimers in the entry of human immunodeficiency virus type 1. J. Virol. 79:12132-12147.
58. Yun SI, et al. 2009. Japanese encephalitis virus-based replicon RNAs/ particles as an expression system for HIV-1 Pr55 Gag that is capable of producing virus-like particles. Virus Res. 144:298 -305.
59. Zhu P, et al. 2006. Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 441:847- 852.